Prioritization of cancer therapeutic targets using CRISPR–Cas9 screensFiona M. Behan, Mathew J. Garnett, Francesco Iorio et al.|Nature|2019Cited by 1.4k
The promise and peril of chemical probesC.H. Arrowsmith, Michael A. Walters, C. Bountra et al.|Nature Chemical Biology|2015Cited by 848
Preclinical target validation using patient-derived cellsA.M. Edwards, Kevin Petrecca, C.H. Arrowsmith et al.|Nature Reviews Drug Discovery|2015Cited by 54